凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2016年第三季度报告全文

公告日期 2016-10-27
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2016 年第三季度报告全文




华兰生物工程股份有限公司

   2016 年第三季度报告




      2016 年 10 月




                                                              1
                                      华兰生物工程股份有限公司 2016 年第三季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管

人员)王建体声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                    2
                                                                      华兰生物工程股份有限公司 2016 年第三季度报告全文




                              第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                       本报告期末                         上年度末              本报告期末比上年度末增减

总资产(元)                                 4,465,868,589.14                4,021,493,476.94                        11.05%

归属于上市公司股东的净资产
                                             4,044,919,495.76                3,657,948,449.65                        10.58%
(元)

                                                        本报告期比上年同期                               年初至报告期末比上
                                     本报告期                                      年初至报告期末
                                                                增减                                         年同期增减

营业收入(元)                       549,725,095.82                    21.20%        1,406,280,739.76                26.62%

归属于上市公司股东的净利润
                                     196,991,969.24                    31.72%          607,309,152.78                32.17%
(元)

归属于上市公司股东的扣除非经
                                     189,452,360.06                    33.34%          528,497,252.35                33.19%
常性损益的净利润(元)

经营活动产生的现金流量净额
                                        --                       --                    218,275,241.55               -32.54%
(元)

基本每股收益(元/股)                          0.2118                  31.72%                   0.6530               32.19%

稀释每股收益(元/股)                          0.2118                  31.72%                   0.6530               32.19%

加权平均净资产收益率                            5.02%                   1.08%                  15.64%                 2.99%

                                                                                                                    单位:元

                           项目                                 年初至报告期期末金额                       说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                          -607,513.31

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                            60,185,469.00
一标准定额或定量享受的政府补助除外)

对外委托贷款取得的损益                                                      10,787,987.42

除上述各项之外的其他营业外收入和支出                                         -2,501,514.62

其他符合非经常性损益定义的损益项目                                          30,976,075.04

减:所得税影响额                                                            14,813,827.27

       少数股东权益影响额(税后)                                               5,214,775.83

合计                                                                        78,811,900.43                    --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因

                                                                                                                              3
                                                                  华兰生物工程股份有限公司 2016 年第三季度报告全文


□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                              单位:股

                                                            报告期末表决权恢复的优先
报告期末普通股股东总数                             45,024                                                          0
                                                            股股东总数(如有)

                                                前 10 名股东持股情况

                                                                     持有有限售条件          质押或冻结情况
     股东名称          股东性质      持股比例        持股数量
                                                                       的股份数量        股份状态        数量

安康                境内自然人            17.84%       165,885,348

重庆市晟康生物
科技开发有限公 境内非国有法人             15.13%       140,737,784                    质押               11,916,000


香港科康有限公
                    境外法人              13.23%       123,022,541


新疆世辰股权投
                    境内非国有法人         3.66%        33,996,224
资有限合伙企业

新华人寿保险股
份有限公司-分
                    其他                   1.35%        12,523,344
红-个人分红
-018L-FH002 深

中央汇金资产管
                    其他                   1.15%        10,679,520
理有限责任公司

华夏人寿保险股
份有限公司-万 其他                        0.92%         8,530,688
能保险产品

天安财产保险股
份有限公司-保 其他                        0.85%         7,927,309
赢理财 1 号

中国银行-嘉实
成长收益型证券 其他                        0.80%         7,400,000
投资基金

新华人寿保险股
份有限公司-分 其他                        0.72%         6,718,648
红-团体分红


                                                                                                                       4
                                                               华兰生物工程股份有限公司 2016 年第三季度报告全文


-018L-FH001 深

                                         前 10 名无限售条件股东持股情况

                                                                                           股份种类
              股东名称                      持有无限售条件股份数量
                                                                                   股份种类           数量

重庆市晟康生物科技开发有限公
                                                                     140,737,784 人民币普通股         140,737,784


香港科康有限公司                                                     123,022,541 人民币普通股         123,022,541

安康                                                                  41,471,338 人民币普通股          41,471,338

新疆世辰股权投资有限合伙企业                                          33,996,224 人民币普通股          33,996,224

新华人寿保险股份有限公司-分
                                                                      12,523,344 人民币普通股          12,523,344
红-个人分红-018L-FH002 深

中央汇金资产管理有限责任公司                                          10,679,520 人民币普通股          10,679,520

华夏人寿保险股份有限公司-万
                                                                       8,530,688 人民币普通股           8,530,688
能保险产品

天安财产保险股份有限公司-保
                                                                       7,927,309 人民币普通股           7,927,309
赢理财 1 号

中国银行-嘉实成长收益型证券
                                                                       7,400,000 人民币普通股           7,400,000
投资基金

新华人寿保险股份有限公司-分
                                                                       6,718,648 人民币普通股           6,718,648
红-团体分红-018L-FH001 深

                                 上述第一、二、三股东存在关联关系,属于一致行动人。新华人寿保险股份有限公司-
上述股东关联关系或一致行动的     分红-个人分红-018L-FH002 深和新华人寿保险股份有限公司-分红-团体分红
说明                             -018L-FH001 深同为新华人寿保险股份有限公司旗下产品。未知其他股东之间是否存在
                                 关联关系,是否属于一致行动人。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
√ 是 □ 否
     公司实际控制人安康先生于2015年11月4日将其直接持有的公司1,800万股公司股份质押给华泰证券办理股票质押式回购
业务,股票质押期限为一年。 2016 年 7 月 15 日,安康先生将已质押的 2,880 万股公司股份(2016 年 6月 7 日,公司实
施每 10 股送 6 股派 4 元的分配方案,质押股票数量由 1,800 万股增加至 2,880 万股,占其直接持有公司股份总数的
17.36%,占公司股份总数的 3.1%), 提前购回并办理完毕上述股权解除质押登记手续。
     截至报告期末,公司实际控制人安康先生直接持有公司股份 16,588.53 万股,占本公司总股本的 17.84%,本次质押解除
后,安康先生所直接持有的公司股份全部解除质押。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                    5
                                                               华兰生物工程股份有限公司 2016 年第三季度报告全文




                                           第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1、应收票据期末余额较期初余额增加54.41%,主要系公司销售货款以票据结算增加所致;
2、应收账款期末余额较期初余额增加214.83%,主要系公司收入增加所致;
3、其他应收款期末余额较期初余额增加219.62%,主要系支付保证金增加所致;
4、存货期末余额较期初余额增加40.58%,主要系公司采浆量增加存货相应增加所致;
5、在建工程期末余额较期初余额增加73.91%,主要系公司工程投入增加所致;
6、其他非流动资产期末余额较期初余额增加50.87%,主要系公司预付工程设备款增加所致;
7、预收款项期末余额较期初余额增加194.62%,主要系公司预收货款增加所致;
8、应交税费期末余额较期初余额增加45.36%,主要系公司收入增加相应企业所得税增加所致;
9、其他应付款期末余额较期初余额增加45.73%,主要系本公司之子公司华兰生物疫苗有限公司预提费用增加所致;
10、资产减值损失本报告期较上年同期增加80.36%,主要系公司应收账款增加相应坏账准备增加所致;
11、投资收益本报告期较上年同期减少44.07%,主要系本期理财收益减少所致;
12、营业外收入本报告期较上年同期增加176.89%,主要系本期收到政府补助增加所致;
13、营业外支出本报告期较上年同期增加80.01%,主要系本公司对外捐赠增加所致;
14、经营活动产生的现金流量净额本报告期较上年同期减少32.54%,主要系采浆量增加相应购买商品、接受劳务支付的现
金增加所致;
15、投资活动产生的现金流量净额本报告期较上年同期减少140.85%,主要系本期理财投资增加所致;
16、筹资活动产生的现金流量净额本报告期较上年同期增加30.80%,主要系本期分配现金股利较上期减少所致。


二、重要事项进展情况及其影响和解决方案的分析说明

□ 适用 √ 不适用


三、公司、股东、实际控制人、收购人、董事、监事、高级管理人员或其他关联方在报告期
内履行完毕及截至报告期末尚未履行完毕的承诺事项

√ 适用 □ 不适用

      承诺事由         承诺方      承诺类型               承诺内容              承诺时间    承诺期限   履行情况

股改承诺

收购报告书或权益变
动报告书中所作承诺

资产重组时所作承诺

                                               为避免同业竞争引起的损害本公
首次公开发行或再融                避免同业竞   司及其他股东利益,本公司实际控 2004 年 06               正在严格
                     实际控制人                                                            长期
资时所作承诺                      争承诺       制人安康先生承诺:"作为本公司 月 25 日                  履行中
                                               实际控制人期间,不在与本公司构



                                                                                                                  6
                                                             华兰生物工程股份有限公司 2016 年第三季度报告全文


                                             成同业竞争的其他公司任职,在其
                                             经营业务中将不会利用其在本公
                                             司及本公司股东中的地位从事任
                                             何有损本公司及其他股东利益的
                                             行为。"

股权激励承诺

                                             公司未来三年(2015-2017 年)的
                                             具体股东回报规划:1、公司可以
                                             采取现金、股票、现金与股票相结
                                             合或者法律、法规允许的其他方式
                                             分配利润。2、根据《公司法》等
                                             有关法律法规及《公司章程》的规
                                             定,在公司盈利且现金能够满足公
                                             司持续经营和长期发展、符合现金
                                             分红条件的前提下,2015-2017 年
                                             每年以现金方式分配的利润应不
                                             低于当年实现的可分配利润的
                                             10%,且连续三年内以现金方式累
                                             计分配的利润不少于该三年实现
其他对公司中小股东              股东回报承   的年均可分配利润的 30%。 3、未 2015 年 04   2015-2017   正在履行
                       董事会
所作承诺                        诺           来三年(2015-2017 年)公司原则 月 22 日     年度        中
                                             上每年度进行一次现金分红,公司
                                             董事会可以根据公司盈利情况及
                                             资金需求状况提议公司进行中期
                                             现金分红。 4、未来三年
                                             (2015-2017)公司可以根据累计
                                             可供分配利润、公积金及现金流状
                                             况,在保证最低现金分红比例和公
                                             司股本规模合理的前提下,为保持
                                             股本扩张与业绩增长相适应,公司
                                             可以采取股票股利方式进行利润
                                             分配,具体分红比例由公司董事会
                                             审议通过后,并提交股东大会审议
                                             决定。

承诺是否按时履行                                               是

如承诺超期未履行完
毕的,应当详细说明未
                                                             不适用
完成履行的具体原因
及下一步的工作计划


四、对 2016 年度经营业绩的预计

2016 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形


                                                                                                                7
                                                              华兰生物工程股份有限公司 2016 年第三季度报告全文


归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2016 年度归属于上市公司股东的净利润变动幅
                                                                      25.00%     至                           35.00%


2016 年度归属于上市公司股东的净利润变动区
                                                                    73,639.87    至                        79,531.06
间(万元)

2015 年度归属于上市公司股东的净利润(万元)                                                                58,911.89

                                            预计 2016 年度归属于上市公司股东的净利润较上年同期增加 25%-35%,
业绩变动的原因说明
                                            主要原因系公司血液制品销售收入增加。


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

√ 适用 □ 不适用

         接待时间                接待方式                接待对象类型                    调研的基本情况索引

                                                                                详见巨潮资讯网(www.cninfo.com.cn)
     2016 年 08 月 30 日         实地调研                    机构               《2016 年 8 月 30 日投资者关系活动记
                                                                                录表》




                                                                                                                       8
                                                        华兰生物工程股份有限公司 2016 年第三季度报告全文




                                     第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:华兰生物工程股份有限公司
                                       2016 年 09 月 30 日
                                                                                                  单位:元

                 项目                       期末余额                              期初余额

流动资产:

    货币资金                                            258,987,365.12                    363,273,966.21

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据                                             58,805,142.40                       38,084,280.00

    应收账款                                            397,792,200.15                    126,349,829.11

    预付款项                                             36,546,035.22                       31,787,823.36

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息

    应收股利

    其他应收款                                               8,705,350.84                     2,723,633.81

    买入返售金融资产

    存货                                                840,501,104.14                    597,901,189.40

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                       1,416,871,000.00                 1,489,861,000.00

流动资产合计                                           3,018,208,197.87                 2,649,981,721.89

非流动资产:

    发放贷款及垫款



                                                                                                             9
                                      华兰生物工程股份有限公司 2016 年第三季度报告全文


    可供出售金融资产

    持有至到期投资

    长期应收款

    长期股权投资                       20,537,882.19                     28,899,310.45

    投资性房地产

    固定资产                          963,514,727.13                    969,007,621.08

    在建工程                          156,287,640.80                     89,865,278.15

    工程物资

    固定资产清理

    生产性生物资产                       1,811,200.07                     1,625,246.20

    油气资产

    无形资产                          195,125,079.08                    199,850,840.91

    开发支出

    商誉

    长期待摊费用                          962,347.55                      1,825,628.58

    递延所得税资产                     27,762,071.94                     26,311,585.76

    其他非流动资产                     81,659,442.51                     54,126,243.92

非流动资产合计                       1,447,660,391.27                 1,371,511,755.05

资产总计                             4,465,868,589.14                 4,021,493,476.94

流动负债:

    短期借款

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据

    应付账款                           48,870,877.38                     44,131,051.55

    预收款项                           21,929,910.31                      7,443,420.03

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                         1,211,876.35                      604,014.38

    应交税费                           47,813,861.57                     32,892,561.42




                                                                                    10
                             华兰生物工程股份有限公司 2016 年第三季度报告全文


    应付利息

    应付股利

    其他应付款                75,832,077.43                     52,036,711.84

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                 195,658,603.04                    137,107,759.22

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款

    预计负债

    递延收益

    递延所得税负债

    其他非流动负债

非流动负债合计

负债合计                     195,658,603.04                    137,107,759.22

所有者权益:

    股本                     930,087,680.00                    581,304,800.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                 394,523,232.03                    382,339,418.70

    减:库存股

    其他综合收益

    专项储备



                                                                            11
                                                                 华兰生物工程股份有限公司 2016 年第三季度报告全文


    盈余公积                                                     331,699,058.29                    331,699,058.29

    一般风险准备

    未分配利润                                               2,388,609,525.44                    2,362,605,172.66

归属于母公司所有者权益合计                                   4,044,919,495.76                    3,657,948,449.65

    少数股东权益                                                 225,290,490.34                    226,437,268.07

所有者权益合计                                               4,270,209,986.10                    3,884,385,717.72

负债和所有者权益总计                                         4,465,868,589.14                    4,021,493,476.94


法定代表人:安康                       主管会计工作负责人:谢军民                        会计机构负责人:王建体


2、母公司资产负债表

                                                                                                           单位:元

                   项目                              期末余额                              期初余额

流动资产:

    货币资金                                                     155,308,631.56                    143,743,883.66

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据                                                      39,496,541.80                       28,821,780.00

    应收账款                                                     172,396,156.04                       31,497,398.93

    预付款项                                                      87,895,492.73                       56,598,255.36

    应收利息

    应收股利

    其他应收款                                                    17,713,419.20                       18,864,956.69

    存货                                                         399,170,235.76                    312,373,938.27

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                                 912,020,000.00                  1,010,000,000.00

流动资产合计                                                    1,784,000,477.09                 1,601,900,212.91

非流动资产:

    可供出售金融资产

    持有至到期投资

    长期应收款                                                     5,379,060.00                        5,379,060.00

    长期股权投资                                                 693,404,579.30                    681,766,007.56

    投资性房地产


                                                                                                                 12
                                        华兰生物工程股份有限公司 2016 年第三季度报告全文


    固定资产                            445,700,591.07                    428,135,400.21

    在建工程                             57,093,059.52                     27,250,753.72

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                            115,917,006.81                    118,458,766.20

    开发支出

    商誉

    长期待摊费用                            962,347.55                      1,825,628.58

    递延所得税资产                         4,190,113.20                     3,650,874.22

    其他非流动资产                       33,408,689.78                     34,646,096.27

非流动资产合计                         1,356,055,447.23                 1,301,112,586.76

资产总计                               3,140,055,924.32                 2,903,012,799.67

流动负债:

    短期借款

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据

    应付账款                             33,218,282.73                     41,282,921.39

    预收款项                             17,622,584.00                      4,327,490.00

    应付职工薪酬                            752,710.98                       156,336.00

    应交税费                             31,948,827.47                     18,763,164.40

    应付利息

    应付股利

    其他应付款                           11,937,171.05                      4,096,035.61

    划分为持有待售的负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                             95,479,576.23                     68,625,947.40

非流动负债:

    长期借款

    应付债券




                                                                                      13
                                              华兰生物工程股份有限公司 2016 年第三季度报告全文


      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款

    预计负债

    递延收益

    递延所得税负债

    其他非流动负债

非流动负债合计

负债合计                                        95,479,576.23                      68,625,947.40

所有者权益:

    股本                                       930,087,680.00                     581,304,800.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                   403,271,029.54                     391,087,216.21

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                   331,699,058.29                     331,699,058.29

    未分配利润                               1,379,518,580.26                 1,530,295,777.77

所有者权益合计                               3,044,576,348.09                 2,834,386,852.27

负债和所有者权益总计                         3,140,055,924.32                 2,903,012,799.67


3、合并本报告期利润表

                                                                                        单位:元

                 项目         本期发生额                             上期发生额

一、营业总收入                             549,725,095.82                         453,555,277.69

    其中:营业收入                         549,725,095.82                         453,555,277.69

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                             324,784,778.94                         274,884,937.78



                                                                                              14
                                           华兰生物工程股份有限公司 2016 年第三季度报告全文


       其中:营业成本                   230,212,564.20                       189,097,677.50

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加               2,612,632.68                         2,502,720.27

             销售费用                    36,292,957.37                        32,789,091.26

             管理费用                    58,545,190.35                        64,838,733.27

             财务费用                    -2,878,565.66                       -12,069,303.29

             资产减值损失                                                     -2,273,981.23

       加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                          2,228,522.70                           -99,744.96
列)

             其中:对联营企业和合营
                                         -1,821,188.10                        -3,166,080.23
企业的投资收益

           汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)      227,168,839.58                       178,570,594.95

       加:营业外收入                     7,258,878.19                         2,961,966.30

           其中:非流动资产处置利得                                                5,672.15

       减:营业外支出                     1,009,709.86                         1,102,813.69

           其中:非流动资产处置损失        436,543.57                            -54,647.83

四、利润总额(亏损总额以“-”号填
                                        233,418,007.91                       180,429,747.56
列)

       减:所得税费用                    35,225,301.69                        27,020,998.39

五、净利润(净亏损以“-”号填列)      198,192,706.22                       153,408,749.17

       归属于母公司所有者的净利润       196,991,969.24                       149,559,248.73

       少数股东损益                       1,200,736.98                         3,849,500.44

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额

       (一)以后不能重分类进损益的


                                                                                         15
                                                               华兰生物工程股份有限公司 2016 年第三季度报告全文


其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

       (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            198,192,706.22                         153,408,749.17

       归属于母公司所有者的综合收益
                                                            196,991,969.24                         149,559,248.73
总额

       归属于少数股东的综合收益总额                           1,200,736.98                           3,849,500.44

八、每股收益:

       (一)基本每股收益                                          0.2118                                 0.1608

       (二)稀释每股收益                                          0.2118                                 0.1608

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:安康                      主管会计工作负责人:谢军民                       会计机构负责人:王建体


4、母公司本报告期利润表

                                                                                                         单位:元

                 项目                          本期发生额                             上期发生额

一、营业收入                                                331,972,845.83                         242,868,646.58

       减:营业成本                                         121,772,878.97                          95,242,326.99



                                                                                                               16
                                           华兰生物工程股份有限公司 2016 年第三季度报告全文


           营业税金及附加                 1,233,668.37                         1,083,430.07

           销售费用                       3,760,385.79                         5,581,305.01

           管理费用                      33,161,520.71                        27,275,157.84

           财务费用                      -1,068,353.54                        -6,704,455.27

           资产减值损失

       加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                          2,228,522.70                           -99,744.96
列)

           其中:对联营企业和合营企
                                         -1,821,188.10                        -3,166,080.23
业的投资收益

二、营业利润(亏损以“-”号填列)      175,341,268.23                       120,291,136.98

       加:营业外收入                      815,330.00                           306,672.15

           其中:非流动资产处置利得                                                5,672.15

       减:营业外支出                      386,306.92                           191,392.64

           其中:非流动资产处置损失        102,226.84                              2,375.84

三、利润总额(亏损总额以“-”号填
                                        175,770,291.31                       120,406,416.49
列)

       减:所得税费用                    26,365,543.69                        19,203,194.98

四、净利润(净亏损以“-”号填列)      149,404,747.62                       101,203,221.51

五、其他综合收益的税后净额

       (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

       (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益



                                                                                         17
                                                        华兰生物工程股份有限公司 2016 年第三季度报告全文


             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                     149,404,747.62                         101,203,221.51

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益


5、合并年初到报告期末利润表

                                                                                                  单位:元

                 项目                   本期发生额                             上期发生额

一、营业总收入                                   1,406,280,739.76                       1,110,657,455.46

       其中:营业收入                            1,406,280,739.76                       1,110,657,455.46

             利息收入

             已赚保费

             手续费及佣金收入

二、营业总成本                                       769,407,373.66                         623,010,558.44

       其中:营业成本                                541,072,343.12                         437,974,325.76

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加                            7,195,906.19                           5,954,211.41

             销售费用                                 51,488,040.83                          43,133,186.50

             管理费用                                184,047,722.16                         161,397,227.36

             财务费用                                -20,214,089.57                         -28,673,847.46

             资产减值损失                              5,817,450.93                           3,225,454.87

       加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                                      22,614,646.78                          40,433,461.08
列)


                                                                                                        18
                                          华兰生物工程股份有限公司 2016 年第三季度报告全文


           其中:对联营企业和合营企
                                        -8,361,428.26                        -8,348,722.95
业的投资收益

           汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)     659,488,012.88                       528,080,358.10

       加:营业外收入                   60,777,591.94                        21,950,426.15

           其中:非流动资产处置利得         80,035.20                             5,672.15

       减:营业外支出                    3,701,150.87                         2,056,049.76

           其中:非流动资产处置损失       687,548.51                           127,892.63

四、利润总额(亏损总额以“-”号填
                                       716,564,453.95                       547,974,734.49
列)

       减:所得税费用                  110,402,078.90                        86,822,369.08

五、净利润(净亏损以“-”号填列)     606,162,375.05                       461,152,365.41

       归属于母公司所有者的净利润      607,309,152.78                       459,476,372.13

       少数股东损益                     -1,146,777.73                         1,675,993.28

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额

       (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

       (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额



                                                                                        19
                                                               华兰生物工程股份有限公司 2016 年第三季度报告全文


             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            606,162,375.05                         461,152,365.41

       归属于母公司所有者的综合收益
                                                            607,309,152.78                         459,476,372.13
总额

       归属于少数股东的综合收益总额                          -1,146,777.73                           1,675,993.28

八、每股收益:

       (一)基本每股收益                                          0.6530                                 0.4940

       (二)稀释每股收益                                          0.6530                                 0.4940

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


6、母公司年初到报告期末利润表

                                                                                                         单位:元

                 项目                          本期发生额                             上期发生额

一、营业收入                                                843,735,124.21                         673,786,829.35

       减:营业成本                                         294,031,808.28                         256,527,173.45

           营业税金及附加                                     3,267,496.86                           3,076,298.08

           销售费用                                          12,549,609.50                          11,515,893.23

           管理费用                                          88,126,247.88                          66,550,905.33

           财务费用                                          -7,800,277.02                         -20,673,375.86

           资产减值损失                                       3,594,926.49                            -111,536.16

       加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                                             12,808,345.41                          32,686,697.04
列)

           其中:对联营企业和合营企
                                                             -8,361,428.26                          -8,348,722.95
业的投资收益

二、营业利润(亏损以“-”号填列)                          462,773,657.63                         389,588,168.32

       加:营业外收入                                        45,566,529.89                           1,309,402.15

           其中:非流动资产处置利得                              34,320.39                               5,672.15

       减:营业外支出                                         2,471,524.56                            749,822.73

           其中:非流动资产处置损失                            263,785.65                               23,528.94

三、利润总额(亏损总额以“-”号填
                                                            505,868,662.96                         390,147,747.74
列)




                                                                                                               20
                                                      华兰生物工程股份有限公司 2016 年第三季度报告全文


     减:所得税费用                                 75,341,060.47                          58,579,381.18

四、净利润(净亏损以“-”号填列)                 430,527,602.49                         331,568,366.56

五、其他综合收益的税后净额

     (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

     (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                   430,527,602.49                         331,568,366.56

七、每股收益:

     (一)基本每股收益

     (二)稀释每股收益


7、合并年初到报告期末现金流量表

                                                                                                单位:元

                 项目                 本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金              1,115,454,558.02                       1,054,526,294.66

     客户存款和同业存放款项净增加


     向中央银行借款净增加额




                                                                                                      21
                                         华兰生物工程股份有限公司 2016 年第三季度报告全文


     向其他金融机构拆入资金净增加


     收到原保险合同保费取得的现金

     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还

     收到其他与经营活动有关的现金     88,888,426.54                         61,675,290.97

经营活动现金流入小计                1,204,342,984.56                     1,116,201,585.63

     购买商品、接受劳务支付的现金    573,387,631.99                        419,833,844.14

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                     134,220,502.68                        112,040,197.85


     支付的各项税费                  171,600,541.10                        137,438,047.58

     支付其他与经营活动有关的现金    106,859,067.24                        123,346,366.24

经营活动现金流出小计                 986,067,743.01                        792,658,455.81

经营活动产生的现金流量净额           218,275,241.55                        323,543,129.82

二、投资活动产生的现金流量:

     收回投资收到的现金             3,378,935,000.00                     1,545,000,000.00

     取得投资收益收到的现金           30,976,075.04                         48,782,184.03

     处置固定资产、无形资产和其他
                                         140,645.49                             51,647.05
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金

投资活动现金流入小计                3,410,051,720.53                     1,593,833,831.08

     购建固定资产、无形资产和其他    191,531,550.80                        169,797,252.36


                                                                                       22
                                                      华兰生物工程股份有限公司 2016 年第三季度报告全文


长期资产支付的现金

       投资支付的现金                          3,305,945,000.00                       1,210,000,000.00

       质押贷款净增加额

       取得子公司及其他营业单位支付
的现金净额

       支付其他与投资活动有关的现金

投资活动现金流出小计                           3,497,476,550.80                       1,379,797,252.36

投资活动产生的现金流量净额                         -87,424,830.27                         214,036,578.72

三、筹资活动产生的现金流量:

       吸收投资收到的现金

       其中:子公司吸收少数股东投资
收到的现金

       取得借款收到的现金

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计

       偿还债务支付的现金

       分配股利、利润或偿付利息支付
                                                   232,521,920.00                         336,034,296.00
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现金

筹资活动现金流出小计                               232,521,920.00                         336,034,296.00

筹资活动产生的现金流量净额                     -232,521,920.00                         -336,034,296.00

四、汇率变动对现金及现金等价物的
                                                        78,784.47                            -130,978.23
影响

五、现金及现金等价物净增加额                   -101,592,724.25                            201,414,434.31

       加:期初现金及现金等价物余额                356,652,009.82                         671,421,714.21

六、期末现金及现金等价物余额                       255,059,285.57                         872,836,148.52


8、母公司年初到报告期末现金流量表

                                                                                                单位:元

                 项目                 本期发生额                             上期发生额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                677,762,816.45                         676,203,612.39



                                                                                                      23
                                         华兰生物工程股份有限公司 2016 年第三季度报告全文


     收到的税费返还

     收到其他与经营活动有关的现金     55,018,520.22                        125,632,529.52

经营活动现金流入小计                 732,781,336.67                        801,836,141.91

     购买商品、接受劳务支付的现金    317,443,017.78                        275,726,766.63

     支付给职工以及为职工支付的现
                                      34,483,505.79                         30,569,826.04


     支付的各项税费                   96,486,403.44                         83,497,112.73

     支付其他与经营活动有关的现金     45,210,716.20                         39,505,158.15

经营活动现金流出小计                 493,623,643.21                        429,298,863.55

经营活动产生的现金流量净额           239,157,693.46                        372,537,278.36

二、投资活动产生的现金流量:

     收回投资收到的现金             2,565,535,000.00                     1,235,000,000.00

     取得投资收益收到的现金           21,169,773.67                         41,035,419.99

     处置固定资产、无形资产和其他
                                          34,761.65                             42,165.05
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金

投资活动现金流入小计                2,586,739,535.32                     1,276,077,585.04

     购建固定资产、无形资产和其他
                                      95,056,542.38                        107,952,152.16
长期资产支付的现金

     投资支付的现金                 2,467,555,000.00                       805,000,000.00

     取得子公司及其他营业单位支付
                                      15,000,000.00                         50,000,000.00
的现金净额

     支付其他与投资活动有关的现金

投资活动现金流出小计                2,577,611,542.38                       962,952,152.16

投资活动产生的现金流量净额             9,127,992.94                        313,125,432.88

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     取得借款收到的现金

     发行债券收到的现金

     收到其他与筹资活动有关的现金

筹资活动现金流入小计

     偿还债务支付的现金

     分配股利、利润或偿付利息支付
                                     232,521,920.00                        336,034,296.00
的现金


                                                                                       24
                                          华兰生物工程股份有限公司 2016 年第三季度报告全文


       支付其他与筹资活动有关的现金

筹资活动现金流出小计                  232,521,920.00                        336,034,296.00

筹资活动产生的现金流量净额            -232,521,920.00                      -336,034,296.00

四、汇率变动对现金及现金等价物的
                                           68,858.34                           -130,978.23
影响

五、现金及现金等价物净增加额           15,832,624.74                        349,497,437.01

       加:期初现金及现金等价物余额   137,121,927.27                        297,461,012.90

六、期末现金及现金等价物余额          152,954,552.01                        646,958,449.91


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。


                                                             华兰生物工程股份有限公司

                                                                     董事长:安康

                                                                    2016年10月27日




                                                                                        25
数据加载中...
prevnext
手机查看股票